The desmoplastic stroma in pancreatic ductal adenocarcinoma (PDAC) severely compromises drug delivery and efficacy. To disrupt stromal barriers, we constructed an all-trans retinoic acid (ATRA)-loaded liposome, FrLip@R, that contained calcium phosphate (CaP) cores and arginine 12-mer peptide (r12) ligands shielded by fibroblast activation protein (FAP)-detachable polyglutamate. Shielding r12 protected FrLip@R from nonspecific uptake, e.g., eluding the mononuclear phagocyte system (MPS) uptake for extended blood retention. Then, FrLip@R could be specifically activated by FAP overexpressed on activated pancreatic stellate cells (PSCs) to expose r12, thereby promoting its PSC uptake via an efficient macropinocytosis pathway. Accordingly, FrLip@R exhibited 2.42- and 2.85-fold higher internalization by in vivo PSCs than r12-modified and unmodified liposomes, respectively. In particular, the FrLip amount in the FAP+ PSCs was 54.46-fold higher than that in the other intratumoral cells. In addition, CaP core dissolution in acidic endosomes promoted ATRA release in the cytoplasm. Through efficient and specific ATRA delivery, FrLip@R induced PSC quiescence and disrupted stromal barriers, enhancing intratumoral drug delivery. Finally, in a murine pancreatic cancer model, FrLip@R combined with gemcitabine exerted antitumor efficacy superior to a 1.5-fold dose of gemcitabine while avoiding its severe side effects. Furthermore, FrLip@R modulation created a microenvironment adverse to tumor growth. Therefore, FrLip@R represents a potent and safe stromal barrier-disrupting agent that can amplify chemotherapeutic efficacy in desmoplastic PDAC.